Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase III NCT07160244

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies — Recruiting • Phase III • Infectious Disease • NCT07160244.

📅 13 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase III
NCT ID
NCT07160244
Start
2025-08-25
Completion
2028-11-06
ClinicaliQ Trial Snapshot
  • BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies — Recruiting • Phase III • Infectious Disease • NCT07160244.
  • Trial testing a group B streptococcus vaccine in pregnant women and babies to assess safety and immune response.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies. This study is seeking healthy pregnant participants: * aged 49 or younger who can join. * between 24 and 36 weeks of gestation ("Gestational age" is a medical term used to describe how far along your pregnancy is) * had a fetal ultrasound examination performed with no major fetal abnormalities observed * documented negative for…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
New super flu vaccine rollout begins as NHS regroups from ‘busiest summer’
Infectious Disease · BBC Health · 31 Aug 2026
The NHS is rolling out an updated flu vaccine this season with modifications designed to improve protection against the Super-K strain, reflecting…
View brief →
Clinical Brief
What is meningitis B and why is a vaccine only being offered to some teenagers?
Infectious Disease · BBC Health · 12 Jun 2026
Meningitis B Vaccine: Key Takeaways for Clinical Practice Limited NHS eligibility: Meningitis B vaccine is not routinely offered to all teenagers; only…
View brief →
Clinical Brief
New HIV report shows progress but inequalities persist in access to testing, PrEP and early diagnosis
Infectious Disease · UKHSA · 14 May 2026
Black African heterosexual women show disproportionately low HIV testing uptake in sexual health services, highlighting a persistent gap in screening coverage among…
View brief →
Clinical Brief
Vaccine schedule change helps protect babies earlier against meningitis B
Infectious Disease · UKHSA · 25 Jun 2026
Meningitis B vaccine schedule has been adjusted to provide earlier protection for infants, with implications for GP recall systems and parental counselling…
View brief →
Clinical Brief
Newborn ICU admissions drop 50% in first full year of RSV maternal vaccine programme
Infectious Disease · UKHSA · 12 Aug 2026
RSV maternal vaccination programme has achieved a 50% reduction in neonatal ICU admissions in its first full year of implementation, demonstrating significant…
View brief →
Clinical Brief
UK begins trials of Ebola vaccine developed in just eight weeks
Infectious Disease · BBC Health · 13 Jul 2026
UK medicines regulator has approved clinical trials of a novel Ebola vaccine developed in eight weeks, demonstrating rapid vaccine development capability in…
View brief →